文献速递脑血管病

西洛他唑联合双联抗血小板治疗用于腔隙性脑卒中二级预防:CSPS.com试验亚组分析

Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
PubMed 文献 · Stroke · 2023-02-03

该研究为CSPS.com前瞻性多中心随机对照试验的预设亚组分析,纳入925例腔隙性脑卒中患者,比较西洛他唑联合双联抗血小板治疗(DAPT)与单联抗血小板治疗(SAPT)的疗效与安全性。结果显示DAPT组缺血性脑卒中复发风险显著低于SAPT组(HR 0.43,95%CI 0.22-0.84),且严重或危及生命的出血风险无显著差异。

要点

  • 腔隙性脑卒中患者中,西洛他唑联合DAPT较SAPT显著降低缺血性脑卒中复发风险(HR 0.43)。
  • DAPT组严重或危及生命出血发生率与SAPT组无显著差异(HR 0.36,95%CI 0.07-1.81)。
  • 该亚组分析结果提示西洛他唑联合DAPT可能作为腔隙性脑卒中二级预防的选项。

核心结论

  • 在腔隙性脑卒中患者中,使用西洛他唑的DAPT相比SAPT在降低复发性缺血性脑卒中发生率方面具有显著获益,且不增加严重或危及生命出血的风险。

研究设计与样本

  • CSPS.com为前瞻性、多中心、随机对照试验,本分析为预设亚组分析,从1884例高危非心源性脑卒中患者中选取925例腔隙性脑卒中患者(平均年龄69.5岁,男性69.4%),于卒中后8至180天入组,随机接受SAPT或西洛他唑联合DAPT,随访0.5至3.5年。

主要发现

  • DAPT组(西洛他唑联合阿司匹林或氯吡格雷)464例(50.2%),SAPT组(阿司匹林或氯吡格雷单药)461例(49.8%)。
  • 随访期间DAPT组缺血性脑卒中12例(1.84/100患者年),SAPT组31例(4.42/100患者年)。
  • 校正多个潜在混杂因素后,DAPT组缺血性脑卒中风险显著低于SAPT组(HR 0.43,95%CI 0.22-0.84)。
  • 严重或危及生命出血发生率两组无显著差异:DAPT组2例(0.31/100患者年) vs SAPT组6例(0.86/100患者年),HR 0.36(95%CI 0.07-1.81)。

临床怎么用

  • 作者结论认为,在腔隙性脑卒中患者中,使用西洛他唑的DAPT相比SAPT在降低复发性缺血性脑卒中发生率方面具有显著获益,且不增加严重或危及生命出血的风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effectiveness of long-term dual antiplatelet therapy (DAPT) to prevent recurrent strokes in patients with lacunar stroke remains unclarified. Therefore, this study aimed to compare and to elucidate the safety and effectiveness of DAPT and single antiplatelet therapy (SAPT) in preventing recurrence in chronic lacunar stroke. METHODS: CSPS.com (Cilostazol Stroke Prevention Study for Antiplatelet Combination) was a prospective, multicenter, randomized controlled trial. In this prespecified subanalysis, 925 patients (mean age, 69.5 years; 69.4% men) with lacunar stroke were selected from 1884 patients with high-risk noncardioembolic stroke, enrolled in the CSPS.com trial after 8 to 180 days following stroke. Patients were randomly assigned to receive either SAPT or DAPT using cilostazol and were followed for 0.5 to 3.5 years. The primary efficacy outcome was the first recurrence of ischemic stroke. The safety outcomes were severe or life-threatening bleeding. RESULTS: The DAPT group receiving cilostazol and either aspirin or clopidogrel and SAPT group receiving aspirin or clopidogrel alone comprised 464 (50.2%) and 461 (49.8%) patients, respectively. Ischemic stroke occurred in 12 of 464 patients (1.84 per 100 patient-years) in the DAPT group and 31 of 461 patients (4.42 per 100 patient-years) in the SAPT group, during follow-up. After adjusting for multiple potential confounding factors, ischemic stroke risk was significantly lower in the DAPT group than in the SAPT group (hazard ratio, 0.43 [95% CI, 0.22-0.84]). The rate of severe or life-threatening hemorrhage did not differ significantly between the groups (2 patients [0.31 per 100 patient-years] versus 6 patients [0.86 per 100 patient-years] in the DAPT and SAPT groups, respectively; hazard ratio, 0.36 [95% CI, 0.07-1.81]). CONCLUSIONS: In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01995370. URL: https://www.umin.ac.jp/ctr; Unique identifier: UMIN000012180.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Nishiyama Y, Kimura K, Otsuka T, et al. Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. Stroke. 2023. PMID: 36734235. doi:10.1161/STROKEAHA.122.039900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。